- Home
- WINT vs NXU Comparison
WINT vs NXU Comparison
Compare WINT & NXU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- NXU
- Stock Information
- Founded
- WINT 1992
- NXU 2016
- Country
- WINT United States
- NXU United States
- Employees
- WINT N/A
- NXU N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- NXU Automotive Aftermarket
- Sector
- WINT Health Care
- NXU Consumer Discretionary
- Exchange
- WINT Nasdaq
- NXU Nasdaq
- Market Cap
- WINT 2.9M
- NXU 2.9M
- IPO Year
- WINT 1995
- NXU 2022
- Fundamental
- Price
- WINT $0.31
- NXU $0.22
- Analyst Decision
- WINT Hold
- NXU
- Analyst Count
- WINT 1
- NXU 0
- Target Price
- WINT $7.00
- NXU N/A
- AVG Volume (30 Days)
- WINT 1.2M
- NXU 288.0K
- Earning Date
- WINT 11-27-2024
- NXU 11-13-2024
- Dividend Yield
- WINT N/A
- NXU N/A
- EPS Growth
- WINT N/A
- NXU N/A
- EPS
- WINT N/A
- NXU N/A
- Revenue
- WINT N/A
- NXU $396,000.00
- Revenue This Year
- WINT N/A
- NXU N/A
- Revenue Next Year
- WINT N/A
- NXU N/A
- P/E Ratio
- WINT N/A
- NXU N/A
- Revenue Growth
- WINT N/A
- NXU 238.46
- 52 Week Low
- WINT $0.32
- NXU $0.21
- 52 Week High
- WINT $14.75
- NXU $4.95
- Technical
- Relative Strength Index (RSI)
- WINT 28.66
- NXU 42.44
- Support Level
- WINT $0.33
- NXU $0.22
- Resistance Level
- WINT $0.42
- NXU $0.24
- Average True Range (ATR)
- WINT 0.03
- NXU 0.02
- MACD
- WINT 0.02
- NXU 0.00
- Stochastic Oscillator
- WINT 1.91
- NXU 45.23
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About NXU Nxu Inc.
Nxu Inc is a technology company developing next-generation electric vehicle (EV) charging, battery, and vehicle technologies for mobility customers. Its technology company building energy and infrastructure solutions for consumers and businesses. Its NxuOne charging technology provides repeatable, consistent power delivery, designed to meet the needs of today's electric vehicles as well as those developed in the future.